Matthew K. Fust, Director: Crinetics Pharmaceuticals CRNX Sell · Filed 24/03/22

Trade details

Type: Insider sale
Amount: $762,650
Shares · price: 17,500 sh · $43.58 a share
Held after: 18,536 sh
Stock: Crinetics Pharmaceuticals CRNX
Person: Matthew K. FustDirector
Trade date: 24/03/20
Filed: 24/03/22
Days to filing: 2 days

Sold 48.6% of holdings

Share of holding sold: 48.6%

Crinetics Pharmaceuticals trades, last 26 weeks

What else happened in Crinetics Pharmaceuticals around then

Filed or reported within 30 days of the trade day · 24/02/19~24/04/19

Matthew K. Fust's recent trades

Matthew K. FustDirector
Sell10b5-1 planCrinetics Pharmaceuticals
Sell10b5-1 plan
Crinetics Pharmaceuticals
CRNX
$716K
16,000 sh
$716K
Filed 25/09/30
Traded 25/09/26
Matthew K. FustDirector
Sell10b5-1 planNeumora Therapeutics
Sell10b5-1 plan
Neumora Therapeutics
NMRA
$239.3K
14,049 sh
$239.3K
Filed 24/10/18
Traded 24/10/18
Matthew K. FustDirector
Sell10b5-1 planNeumora Therapeutics
Sell10b5-1 plan
Neumora Therapeutics
NMRA
$131.6K
7,739 sh
$131.6K
Filed 24/10/18
Traded 24/10/17
Matthew K. FustDirector
Sell10b5-1 planCrinetics Pharmaceuticals
Sell10b5-1 plan
Crinetics Pharmaceuticals
CRNX
$796.3K
17,500 sh
$796.3K
Filed 24/03/22
Traded 24/03/20
Matthew K. FustDirector
Sell10b5-1 planCrinetics Pharmaceuticals
Sell10b5-1 plan
Crinetics Pharmaceuticals
CRNX
$544.6K
12,500 sh
$544.6K
Filed 24/03/22
Traded 24/03/20